Use of infliximab in the prevention and delay of colectomy in severe steroid dependant and refractory ulcerative colitis

Willert, Robert P.; Lawrence, Ian Craig; Koutroubakis, Ioannis E.; Brisinda, Giuseppe; Ukleja, Andrew
April 2008
World Journal of Gastroenterology;4/28/2008, Vol. 14 Issue 16, p2544
Academic Journal
AIM: To determine if infliximab can prevent or delay surgery in refractory ulcerative colitis (UC). METHODS: UC patients who failed to have their disease controlled with conventional therapies and were to undergo colectomy if infliximab failed to induce a clinical improvement were reviewed. Patients were primarily treated with a single 5 mg/kg infliximab dose. The Colitis Activity Index (CAI) was used to determine response and remission. Data of 8 wk response and colectomy rates at 6 mo and 12 mo were collected. RESULTS: Fifteen patients were included, 7 with UC unresponsive or intolerant to IV hydrocortisone, and 8 with active disease despite oral steroids (all but one with therapeutic dosage and duration of immunomodulation). All the IV hydrocortisone-resistant/intolerant patients had been on azathioprine/6-MP < 8 wk. At 8 wk, infliximab induced a response in 86.7% (13/15) with 40% in remission (6/15). Within 6 mo of treatment 26.7% (4/15) had undergone colectomy and surgery was avoided in 46.6% (7/15) at 12 mo. The colectomy rate at 12 mo in those on immunomodulatory therapy < 8 wk at time of infliximab was 12.5% (1/8) compared with 100% (7/7) in patients who were on long-term maintenance immunomodulators (P < 0.02).CONCLUSION: Infliximab prevented colectomy due to active disease in immunomodulatory-naïve, refractory UC patients comparable to the use of Cyclosporine. In patients, however, on effective dosage and duration of immunomodulation at time of infliximab therapy colectomy was not avoided.


Related Articles

  • DISCUSSION.  // American Journal of Gastroenterology;Oct1956, Vol. 26 Issue 4, p447 

    Discusses results obtained from the surgical treatment of ulcerative colitis in the U.S. Details on the incidence of cancer in retained colons in patients not undergoing colectomy for ulcerative colitis; Percentage of patients treated medically for the disease; Accounts on the comparative...

  • The "Natural History" of Inflammatory Bowel Disease and Therapeutic Decisions. Janowitz, Henry D. // American Journal of Gastroenterology;Jun1987, Vol. 82 Issue 6, p498 

    Examines the effectiveness of therapeutics in treating inflammatory bowel disease. Effect of cortisone on ulcerative colitis according to a 1955 study by Truelove and Witts; Maintenance therapy in Crohn's disease; Impact of colectomy on ulcerative colitis.

  • Acute Severe Colitis: Infliximab and/or Cyclosporine? Fabro, Mauro; Szabo, Hajnalka; Terrosu, Giovanni; Avellini, Claudio; Tabuso, Maria; Fiorino, Gionata; Sorrentino, Dario // Current Drug Targets;Sep2011, Vol. 12 Issue 10, p1448 

    Acute severe ulcerative colitis is a serious condition that requires early hospitalization, with intensive monitoring and treatment. Despite the recent progress in the medical approach of Inflammatory Bowel Diseases acute severe ulcerative colitis remains a clinical challenge, with a mortality...

  • Steroid-Refractory Severe Ulcerative Colitis. Moss, Alan C.; Peppercorn, Mark A. // Drugs;2008, Vol. 68 Issue 9, p1157 

    Approximately 15% of patients with ulcerative colitis will experience a severe episode requiring hospitalization. Although intravenous corticosteroids are the current first-line therapy for these patients, about 30% of patients do not respond to corticosteroids and require either an alternative...


    Despite widespread use of corticosteroids and adjunctive therapies in acute severe colitis, many patients will require colectomy during admission. A recent BSG survey estimated the national colectomy rate at 28%. Several studies have identified clinical and blood variables. A proportion of...

  • Management of Inflammatory Bowel Disease. Grover, Purva; Kamat, Deepak // Clinical Pediatrics;May2007, Vol. 46 Issue 4, p359 

    The article provides information about the management of inflammatory bowel disease (IBD) and discusses the use of infliximab as a treatment for IBD in the U.S. Patients with IBD are advised to manage the disease through diet and lifestyle changes, pharmacologic treatments, surgical intervention...

  • Infliximab: the evidence for its place in therapy in ulcerative colitis. Assche, Gert Van; Vermeire, Séverine; Rutgeerts, Paul // Core Evidence;2007, Vol. 2 Issue 3, p151 

    Introduction: Refractory ulcerative colitis has a high, unmet medical need for avoiding steroid dependency and avoiding colectomy. Controlled trials with biologic agents have recently been reported. Aims: We aimed to review the current evidence supporting the use of the monoclonal antitumor...

  • The management of dysplasia associated with ulcerative colitis: colectomy versus continued surveillance. Friedlich, Martin S.; Guindi, Maha; Stern, Hartley S. // Canadian Journal of Surgery;Jun2004, Vol. 47 Issue 3, p212 

    The article focuses on the management of dysplasia associated with ulcerative colitis (UC). Colectomy versus continued surveillance in patients with longstanding UC is a challenging decision. Several factors must be considered. Often such patients have quiescent disease, making the prospect of...

  • COLECTOMY DURING ACUTE PHASE OF CHRONIC ULCERATIVE COLITIS. Schroeder, Morrison // American Journal of Gastroenterology;Oct1956, Vol. 26 Issue 4, p443 

    Presents several cases of patients diagnosed with ulcerative colitis in the U.S. Use of colectomy in managing the acute phase of the disease; Causes of death in acute fulminating ulcerative colitis; Risk factors of the disease.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics